Basic Information
| LncRNA/CircRNA Name | LINC00511 |
| Synonyms | LINC00511, LCAL5, onco-lncRNA-12 |
| Region | GRCh38_17:72323123-72640472 |
| Ensemble | ENSG00000227036 |
| Refseq | NR_033876 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic ductal adenocarcinoma |
| ICD-0-3 | C25.3 |
| Methods | qPCR, Luciferase reporter assay, Western blot, RIP |
| Sample | pancreatic cancer, cell lines (PANC-1, MIA PaCa-2, Capan-2, SW1990, ASPC-1, BxPC-3) |
| Expression Pattern | up-regulated |
| Function Description | The aberrant up-regulation of linc00511 was detected in PDAC cell lines and patient specimens compared with controls.An increase in linc00511 expression indicates the adverse clinical pathological characteristics and poor prognosis. linc00511 depletion in PDAC cells decreased proliferation,migration, invasion and endothelial tube formation.linc00511 could up-regulate VEGFA via its competing endogenous RNA (ceRNA) activity on hsa-miR-29b-3p. |
| Pubmed ID | 28984028 |
| Year | 2017 |
| Title | Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma. |
External Links
| Links for LINC00511 | GenBank HGNC NONCODE |
| Links for pancreatic ductal adenocarcinoma | OMIM COSMIC |